Helus, Pharmas

Helus Pharma's Upgraded Price Target Meets a Sobering Set of Trial Footnotes

Published on 11/18/2026 at 03:01 | Editorial boerse-global.de
Helus Pharma's HLP003 hit its Phase 3 primary endpoint, but three serious adverse events and a $103.1 million quarterly loss keep the risk picture open.
Helus Pharma Inc. Illustration mit AI erstellt.

Helus Pharma handed investors two very different documents this week. One was a Phase 3 readout that cleared its primary endpoint with room to spare. The other was a quarterly loss that more than tripled. The market, given a day to digest both, marked the stock down 6.6% on Tuesday evening — even as Lucid Capital lifted its price target to $79 from $52 and reiterated a buy rating.

That split verdict captures the central tension in the Helus story. A statistically robust treatment effect does not, on its own, settle the questions of safety or of how the company funds its next steps.

What APPROACH Actually Showed

The trial, a Phase 3 study of HLP003 as an add-on to existing antidepressants in major depression, enrolled 222 adults. At six weeks, the MADRS depression score fell 19.5 points among patients on HLP003, versus 11.9 points in the placebo arm. The placebo-adjusted difference came to 7.6 points, with a p-value below 0.0001.

The separation held at twelve weeks, when the adjusted gap stood at 7.0 points, again with a p-value under 0.0001. Helus said the study hit its primary endpoint along with key secondary endpoints.

Should investors sell immediately? Or is it worth buying Helus Pharma Inc.?

One design detail matters for interpretation: HLP003 was tested alongside an antidepressant, not as monotherapy. The results describe that combination and say nothing about HLP003 used on its own. And a positive efficacy readout is not an approval — the drug has yet to clear regulators.

Three Serious Events Sit Alongside the Efficacy Signal

Helus disclosed three treatment-related serious adverse events. The presentation identified two reports of depression and one suicide attempt. According to the company, side effects were mostly mild to moderate and transient.

Both facts have to be held at once. The company's general characterization does not erase the serious cases, and the existence of those cases does not invalidate the efficacy data. The findings have not yet been peer-reviewed, which keeps a final judgment on the benefit-risk balance out of reach for now.

Two more milestones frame the timeline: results from the additional registration-relevant EMBRACE study are expected in Q4 2027, and Helus plans to file for approval in 2028. Both are still ahead — the application is a plan, not a submission already on file.

The Loss Grew, but the Cash Burn Is a Separate Question

In the second quarter of fiscal 2027, Helus posted a net loss of $103.1 million, against $33.7 million a year earlier. A chunk of that increase reflects share-based compensation, so total operating expenses should not be read as a matching cash outflow. Excluding share-based compensation, operating costs in the quarter were $39.6 million.

Helus Pharma Inc. at a turning point? This analysis reveals what investors need to know now.

The balance sheet showed $171.1 million in liquid funds as of September 30, 2026. That figure alone does not yield a reliable funding runway: a net loss is not the same as cash consumption, and the company's own cost structure complicates any simple division.

Reading the Whole Board

Lucid Capital's more bullish target stands in sharp contrast to the share price action, and neither extreme tells the full story. Helus has delivered positive efficacy data, still has to work through serious safety findings, and reported a substantially wider quarterly loss.

Anyone focused only on the raised target is flattening that picture, just as anyone reading a single down day as a verdict on the trial is overreaching. The clinical progress is real; it does not retire the risks that remain between here and a possible approval.

Ad

Helus Pharma Inc. Stock: New Analysis - 18 November

Fresh Helus Pharma Inc. information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Helus Pharma Inc. analysis...

Disclaimer...
en | CA23256X4075 | HELUS | boerse | 70529178 |